‘MRNA vaccine development support project in preparation for pandemic’… “From non-clinical trials to product approval”
[질병관리청 제공. 재판매 및 DB 금지]
(Seoul = Yonhap News) Reporter Kim Jan-di = The Korea Disease Control and Prevention Agency has set a goal of securing a domestically produced COVID-19 messenger ribonucleic acid (mRNA) vaccine by 2028 and is providing all-round support.
On the 18th, the Korea Disease Control and Prevention Agency held an information session for the ‘Pandemic Preparedness mRNA Vaccine Development Support Project’ to support research and development of domestic pharmaceutical and bio companies in preparation for future infectious disease pandemics.
This project aims to support mRNA vaccine platform development research from non-clinical to clinical trials from 2025 to 2028 and obtain product approval for COVID-19 mRNA vaccines.
advertisement
So far, the Korea Disease Control and Prevention Agency has been working to secure key technologies, such as vaccine prototypes and mRNA platforms, for infectious diseases that are likely to become the next pandemic.
An mRNA vaccine is a vaccine developed using mRNA, which contains the genetic information of the virus. The COVID-19 vaccine developed by Pfizer and Moderna is a representative mRNA vaccine.
Although mRNA platform vaccines are difficult to develop, they have the advantage of being able to quickly respond to mutations by simply replacing the genetic information of the virus.
The Korea Disease Control and Prevention Agency judged that the development of a domestically produced mRNA vaccine was necessary, considering that there were various difficulties such as supply and demand and costs due to the absence of a domestically produced vaccine during the domestic COVID-19 epidemic.
Accordingly, in order to focus on supporting the entire process from non-clinical to approval of mRNA vaccine development, we will boldly invest the budget and provide technical and institutional support, including eliminating unnecessary regulations. A government-wide integrated support system will also be established.
Through the support project, the plan is to verify domestic technology for developing mRNA vaccines and strengthen supply and demand capabilities by developing vaccines in advance to prepare for pandemics.
The Korea Disease Control and Prevention Agency expected that by securing vaccine prototypes based on the mRNA platform for high-priority viruses in advance, rapid commercialization would be possible within 100 to 200 days when an actual pandemic occurs.
Director Ji Young-mi of the Korea Disease Control and Prevention Agency said, “Vaccine core technologies such as mRNA are national strategic technologies to quickly respond to new infectious diseases and require continuous investment. If we develop vaccines through our own technology, we can stably supply vaccines domestically. “We will be able to pioneer the global export market,” he emphasized.
Corporate meeting for mRNA vaccine development support project
(Seoul = Yonhap News) Ji Young-mi, Commissioner of the Korea Disease Control and Prevention Agency, celebrated with attendees at a meeting held at the LW Convention Center in Jung-gu, Seoul on the 13th to discuss with pharmaceutical companies and related associations ‘measures to secure sovereignty over mRNA vaccines in preparation for future pandemics’. I’m filming. 2024.5.13 [질병관리청 제공. 재판매 및 DB 금지] photo@yna.co.kr
Report via KakaoTalk okjebo
Unauthorized reproduction/redistribution, AI learning and use prohibited>
2024/10/18 10:44 Sent
